News

The US Food and Drug Association has granted approval to irinotecan liposome with oxaliplatin, fluorouracil, and leucovorin for the treatment of patients with metastatic pancreatic adenocarcinoma in the first-line setting.

Results from a retrospective cohort study found that molecular classification can predict prognosis and relapse patterns among patients with low or intermediate-risk endometrial cancer.

Get a summary of the changes in the NCCN guidelines regarding radiopharmaceuticals, secondary hormone therapy, and treatments for metastatic castration-sensitive prostate cancer.

A fractionated schedule of gemtuzumab ozogamicin resulted in improved overall survival and a greater reduction in measurable residual disease among older patients with acute myeloid leukemia, compared to single-dose gemtuzumab ozogamicin.

Pallawi Torka, MD, and colleagues investigated whether a geriatric assessment or its component measures can predict toxicity in older adults with non-Hodgkin lymphoma.

Daratumumab, bortezomib, lenalidomide, and dexamethasone have shown significant results in progression-free survival rates for patients with newly diagnosed multiple myeloma.

Long-term follow-up data from the phase 3 CheckMate-214 trial demonstrated that nivolumab plus ipilimumab improved survival and response compared to sunitinib among patients with advanced renal cell carcinoma.

Jennifer L. Crombie, MD, and colleagues evaluated the real-world clinical effectiveness and safety of commercial lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphoma.

In a recent study, Talha Munir, PhD, and colleagues investigated whether personalization of ibrutinib and venetoclax treatment according to measurable residual disease has an impact on patients’ progression-free survival.

Danai Dima, MD, and colleagues examined the real-world safety and efficacy of teclistamab for treating patients with relapsed refractory multiple myeloma who have had at least four prior lines of therapy.